BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-549@pharmaconomics
DTSTAMP:20260707T034434Z
DTSTART;VALUE=DATE:20260331
DTEND;VALUE=DATE:20260401
SUMMARY:AGIO AdCom — mitapivat (estimated date)
DESCRIPTION:An FDA advisory committee reviews mitapivat for sickle cell disease around ~ Mar 31\, 2026. The panel's public vote often front-runs the agency's final verdict — and the share price.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1439222/000143922226000023/agio-21226xfyxex991earning.htm\n\nTrack it: https://www.pharmaconomics.com/e/549
URL:https://www.pharmaconomics.com/e/549
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:AGIO catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR